Furthermore, the expression of IL-10 is lower in patients who have developed neutralizing antibodies to IFN-β than in other untreated MS patients and healthy control subjects, suggesting that endogenous IFN-β is involved in the induction of IL-10 [9]. The gene discussed is IFNB1; the disease is myeloid sarcoma.